Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LSB Stock Forecast 2026-2027
$0.77
Current Price
$52.66M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to LSB Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
LSB Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
-61.5%
1 Year Change
0.0%
Year-to-Date Change
-80.7%
From 52W High of $3.99
+156.6%
From 52W Low of $0.30
📊 TOP ANALYST CALLS
Did LSB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if YS Biopharma is one of their latest high-conviction picks.
Latest LSB Stock Price Targets & Analyst Predictions
LSB has shown a year-to-date change of 0.0% and a 1-year change of -61.5%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for LSB. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LSB Analyst Ratings
0
Buy
0
Hold
0
Sell
LSB Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.77
Latest LSB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LSB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Lakeshore Biopharma Co. Ltd. (LSB) Competitors
The following stocks are similar to YS Biopharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Lakeshore Biopharma Co. Ltd. (LSB) Financial Data
Valuation Metrics
Market Cap
$52.66M
Enterprise Value
$27.22M
P/E Ratio
N/A
PEG Ratio
-2.5x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
+27.7%
Gross Margin
+81.9%
Operating Margin
-68.8%
Net Margin
-16.3%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+776.4%
Current Ratio
1.0x
Debt/Equity
72.5x
ROE
-18.4%
ROA
-2.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Lakeshore Biopharma Co. Ltd. (LSB) Business Model
About Lakeshore Biopharma Co. Ltd.
What They Do
Develops and manufactures biopharmaceutical products.
Business Model
Lakeshore Biopharma generates revenue by innovating and delivering therapies in oncology, immunology, and rare genetic disorders. The company invests heavily in research and development, focusing on clinical trials and collaborations to expedite the introduction of new treatments to the market.
Additional Information
With a strong commitment to advancing personalized medicine, Lakeshore Biopharma plays a crucial role in the healthcare sector by addressing gaps in treatment options and providing therapies for underserved patient populations. Its robust pipeline and strategic partnerships further enhance its ability to tackle complex and chronic diseases.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
758
CEO
Mr. Wang Xu
Country
China
IPO Year
2021
Website
www.lakeshorebio.comLakeshore Biopharma Co. Ltd. (LSB) Latest News & Analysis
Latest News
Quick Summary
LakeShore Biopharma received a legal notice from a Buyer Group, including Oceanpine entities, on February 4, 2026. The implications for investors remain to be clarified.
Why It Matters
LakeShore Biopharma's legal notice from a buyer group may indicate a potential acquisition or merger, impacting its stock value and market position, crucial for investor decisions.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
LakeShore Biopharma will hold an extraordinary general meeting on February 12, 2026, in Beijing to discuss company matters. It trades on OTC markets under LSBCF and LSBWF.
Why It Matters
The announcement of an extraordinary general meeting may indicate significant developments or decisions ahead, impacting LakeShore Biopharma's strategy and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
LakeShore Biopharma has entered into a merger agreement with Oceanpine Skyline Inc., with a transaction valued at approximately $37 million, making LakeShore a subsidiary of Oceanpine.
Why It Matters
The merger signifies a strategic consolidation in the biopharmaceutical sector, potentially enhancing LakeShore's resources and capabilities while impacting its stock valuation and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
LakeShore Biopharma (Nasdaq: LSB) announced that its ordinary shares and warrants are suspended from trading on Nasdaq, effective September 22, 2025.
Why It Matters
Suspension of LakeShore Biopharma's shares on Nasdaq indicates potential financial distress, regulatory issues, or operational challenges, negatively impacting investor confidence and market perception.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
LakeShore Biopharma (Nasdaq: LSB) received a notice from Nasdaq that it is non-compliant with the Bid Price Rule due to its share price being below $1.00 for 30 consecutive days.
Why It Matters
LakeShore Biopharma's non-compliance with Nasdaq's bid price rule could lead to delisting, affecting stock liquidity and investor confidence, potentially impacting share value.
Source: PRNewsWire
Market Sentiment:
Neutral
LakeShore Biopharma Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
6 months ago
Quick Summary
LakeShore Biopharma Co., Ltd (Nasdaq: LSB) has formed a special committee to evaluate a revised non-binding proposal, hiring Kroll, Gibson, Dunn & Crutcher, and Maples and Calder for advisory and legal support.
Why It Matters
The hiring of financial and legal advisors indicates potential strategic moves, such as mergers or acquisitions, which can significantly impact stock value and company direction.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About LSB Stock
What is Lakeshore Biopharma Co. Ltd.'s (LSB) stock forecast for 2026?
Analyst forecasts for Lakeshore Biopharma Co. Ltd. (LSB) are not currently available. The stock is trading at $0.77.
Is LSB stock a good investment in 2026?
Analyst ratings for LSB are not currently available. The stock is currently trading at $0.77. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LSB stock?
Price predictions from Wall Street analysts for LSB are not currently available. The stock is trading at $0.77.
What is Lakeshore Biopharma Co. Ltd.'s business model?
Lakeshore Biopharma generates revenue by innovating and delivering therapies in oncology, immunology, and rare genetic disorders. The company invests heavily in research and development, focusing on clinical trials and collaborations to expedite the introduction of new treatments to the market.
What is the highest forecasted price for LSB Lakeshore Biopharma Co. Ltd.?
Price targets from Wall Street analysts for LSB are not currently available. The stock is trading at $0.77.
What is the lowest forecasted price for LSB Lakeshore Biopharma Co. Ltd.?
Price targets from Wall Street analysts for LSB are not currently available. The stock is trading at $0.77.
What is the overall LSB consensus from analysts for Lakeshore Biopharma Co. Ltd.?
Analyst ratings for LSB are not currently available. The stock is trading at $0.77.
How accurate are LSB stock price projections?
Stock price projections, including those for Lakeshore Biopharma Co. Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 15, 2026 2:07 PM UTC